Prevention of viral infections in families of recipients of solid organs

Current COVID-19 pandemic demands improvements in antiviral prophylaxis. Tyloron, as biological interferon activator, has been synthesized in the 70th of previous century. We used Tyloron in 60 patients – relatives and partners living together with solid organ transplant recipients – in autumn 2020, during second wave of the SARS-CoV‑2 pandemic. Results were compared with 60 patients used other means of antiviral prophylaxis. In patients taking Tyloron the number of febrile episodes was significantly lower (р < 0.02).